The global allergy immunotherapy market size is calculated at USD 2.12 billion in 2025 and is expected to reach around USD 4.50 billion by 2034, growing at a CAGR of 8.73% for the forecasted ...

Galderma today announced that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency and Swissmedi ...

The FDA has granted a fast track designation to rezpegaldesleukin for treating patients aged 12 years and older with moderate ...

Treating eczema starts with a solid skincare routine, but you may need more than just moisturizer to get you through a ...

Premorbid allergic diseases are linked with the development of age-related macular degeneration (AMD), however, the risk of allergic diseases among patients with AMD is largely unknown.To evaluate the ...

RAPT Therapeutics pivoted from a failed inflammation asset (RPT193) to focus on RPT904 for food allergies. Find out whether ...

With the help of prescription medications and a whole lot of moisturizing, it’s possible to keep dermatitis under control.

Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union (EU). Nemluvio is now ...

Nemluvio is the first approved monoclonal antibody that specifically targets IL-31 receptor alpha, inhibiting the signaling of IL-31, which drives itch and is involved in inflammation and skin barrier ...

According to Statifacts, the global allergy diagnostic market size is calculated at USD 6,711 million in 2025 and is expected ...